DE69806024T2 - Erkennung und identifizierung von menschlichem papillomavirus durch pcr und typ-spezifischer reverser hybridisierung - Google Patents
Erkennung und identifizierung von menschlichem papillomavirus durch pcr und typ-spezifischer reverser hybridisierungInfo
- Publication number
- DE69806024T2 DE69806024T2 DE69806024T DE69806024T DE69806024T2 DE 69806024 T2 DE69806024 T2 DE 69806024T2 DE 69806024 T DE69806024 T DE 69806024T DE 69806024 T DE69806024 T DE 69806024T DE 69806024 T2 DE69806024 T2 DE 69806024T2
- Authority
- DE
- Germany
- Prior art keywords
- seq
- hpv
- type
- dna
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 49
- 238000009396 hybridization Methods 0.000 title abstract description 70
- 241000701806 Human papillomavirus Species 0.000 title description 300
- 239000000523 sample Substances 0.000 claims abstract description 191
- 238000000034 method Methods 0.000 claims abstract description 64
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 29
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 29
- 239000012634 fragment Substances 0.000 claims abstract description 27
- 239000012472 biological sample Substances 0.000 claims abstract description 20
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 4
- 101100256840 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) sgpB gene Proteins 0.000 claims description 45
- 101100256841 Glossina morsitans morsitans sgp2 gene Proteins 0.000 claims description 45
- 101100256838 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) sgpA gene Proteins 0.000 claims description 39
- 101100256839 Glossina morsitans morsitans sgp1 gene Proteins 0.000 claims description 39
- 101150002602 Psap gene Proteins 0.000 claims description 39
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 13
- 101100256842 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) sgpC gene Proteins 0.000 claims description 10
- 101100534514 Mus musculus Stmn1 gene Proteins 0.000 claims description 8
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 claims 2
- 101100107644 Arabidopsis thaliana ABI5 gene Proteins 0.000 claims 1
- 230000003321 amplification Effects 0.000 abstract description 43
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 43
- 101150075239 L1 gene Proteins 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 291
- 150000007523 nucleic acids Chemical class 0.000 description 257
- 102000039446 nucleic acids Human genes 0.000 description 255
- 108020004707 nucleic acids Proteins 0.000 description 255
- 230000000692 anti-sense effect Effects 0.000 description 252
- 239000013615 primer Substances 0.000 description 199
- 238000003752 polymerase chain reaction Methods 0.000 description 85
- 239000013612 plasmid Substances 0.000 description 33
- 238000003556 assay Methods 0.000 description 22
- 238000001574 biopsy Methods 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 230000000295 complement effect Effects 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
- 238000012300 Sequence Analysis Methods 0.000 description 14
- 238000011161 development Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000003205 genotyping method Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002751 oligonucleotide probe Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 206010008342 Cervix carcinoma Diseases 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 8
- 235000020958 biotin Nutrition 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- 201000010881 cervical cancer Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000004392 genitalia Anatomy 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000002987 primer (paints) Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000013081 phylogenetic analysis Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 208000009608 Papillomavirus Infections Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 208000020077 squamous cell intraepithelial neoplasia Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000002944 PCR assay Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011896 sensitive detection Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- -1 alkyl phosphoric acid esters Chemical class 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012568 clinical material Substances 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 101100243026 Arabidopsis thaliana PCO3 gene Proteins 0.000 description 1
- 101100243027 Arabidopsis thaliana PCO4 gene Proteins 0.000 description 1
- 101100149390 Arabidopsis thaliana SGPP gene Proteins 0.000 description 1
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000883306 Huso huso Species 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 231100001222 nononcogenic Toxicity 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Verfahren zum Nachweis und/oder Identifizierung von HPV in einer biologischen
Probe, umfassend die Schritte:
(i) amplifizieren eines Polynukleinsäure-Fragments von HPV unter Verwendung von:
- einem 5'-Primer, der spezifisch mit der A-Region oder der.B-Region des Genoms mindestens
eines HPV-Typs hybridisiert, wobei die A-Region oder die B-Region in Fig. 1 dargestellt ist,
und
- einem 3'-Primer, der spezifisch mit der C-Region des Genoms mindestens eines HPV-Typs
hybridisiert, wobei die C-Region in Fig. 1 dargestellt ist,
(ii) hybridisieren der amplifizierten Fragmente aus Schritt (i) mit mindestens einer Sonde, die
in der Lage ist, spezifisch mit der D-Region mindestens eines HPV-Typs zu hybridisieren,
wobei die D-Region in Fig. 1 dargestellt ist.
2. Verfahren nach Anspruch 1, ferner dadurch gekennzeichnet, dass:
- das 3'-Ende des spezifisch mit der A-Region des Genoms mindestens eines HPV-Typs
hybridisierenden 5'-Primers, an Position 6572 des Genoms von HPV 16 oder an der
entsprechenden Position irgendeines anderen HPV-Genoms wie in Fig. 1 dargestellt,
lokalisiert ist und/oder
- das 3'-Ende des spezifisch mit der B-Region des Genoms mindestens eines HPV-Typs
hybridisierenden 5'-Primers, an Position 6601 des Genoms von HPV 16 oder an der
entsprechenden Position irgendeines anderen HPV-Genoms wie in Fig. 1 dargestellt,
lokalisiert ist und/oder
- das 3'-Ende des spezifisch mit der C-Region des Genoms mindestens eines HPV-Typs
hybridisierenden 3'-Primers, an Position 6624 des Genoms von HPV 16 oder an der
entsprechenden Position irgendeines anderen HPV-Genoms wie in Fig. 1 dargestellt,
lokalisiert ist.
3. Ein Verfahren nach Anspruch 2, femer dadurch gekennzeichnet, dass:
- der spezifisch mit der A-Region hybridisierende 5'-Primer aus der folgenden Liste
ausgewählt ist:
SGP3 (SEQ ID NO 2), SGP3A (SEQ ID NO 3), SGP3B (SEQ ID NO 4), SGP3C (SEQ
ID NO 10), SGP3D (SEQ ID NO 11), SGP3E (SEQ ID NO 12), SGP3F (SEQ ID NO
13), SGP3G (SEQ ID NO 14) und/oder
- der spezifisch mit der B-Region hybridisierende 5'-Primer aus der folgenden Liste
ausgewählt ist:
SGP1 (SEQ ID NO 6), SGPIA (SEQ ID NO 15), SGPIB (SEQ ID NO 16), SGPIC
(SEQ ID NO 17), SGP ID (SEQ ID NO 18) und/oder
der spezifisch mit der C-Region hybridisierende 3'-Primer aus der folgenden Liste ausgewählt
ist:
SGP2 (SEQ ID NO 9), SGP2A (SEQ ID NO 8), SGP2B (SEQ ID NO 19), SGP2C (SEQ
ID NO 20), SGP2D (SEQ ID NO 21), SGP2E (SEQ ID NO 22), SGP2F (SEQ ID NO
23), SGP2H (SEQ ID NO 98), SGP2I (SEQ ID NO 154), SGP2 J (SEQ ID NO 155),
SGP2K (SEQ ID NO 156), SGP2L (SEQ ID NO 157), SGP2M (SEQ ID NO 158),
SGP2N (SEQ DD NO 159), SGP2P (SEQ ID NO 160).
4. Verfahren nach einem der Ansprüche 1 bis 3, femer dadurch gekennzeichnet, dass die
in Schritt (ii) erwähnte Sonde in der Lage ist, spezifisch mit der D-Region des Genoms nur
eines HPV-Typs zu hybridisieren und daher die spezifische Identifizierung dieses HPV-Typs
ermöglicht, wenn dieser Typ in einer biologischen Probe vorliegt.
5. Verfahren nach einem der Ansprüche 1 bis 3, femer dadurch gekennzeichnet, dass die
in Schritt (ii) erwähnte Sonde in der Lage ist, spezifisch mit der D-Region von mehr als einem
HPV-Typ zu hybridisieren und daher den Nachweis von irgendeinem des mehr als einem
HPV-Typ ermöglicht, wenn irgendeiner der Typen in einer biologischen Probe vorliegt.
6. Verfahren nach Anspruch 4, femer dadurch gekennzeichnet, dass die Sonde, die in der
Lage ist, spezifisch mit der D-Region des Genoms nur eines HPV-Typs zu hybridisieren,
insbesondere mit der E-Region hybridisiert, wobei die E-Region eine Subregion der D-Region
wie in Fig. 1 dargestellt ist.
7. Verfahren nach Anspruch 4, femer dadurch gekennzeichnet, dass die Sonde, die in der
Lage ist, spezifisch mit der D-Region des Genoms nur eines HPV-Typs zu hybridisieren,
insbesondere mit der 22 Bp-Region hybridisiert, die zwischen der B-Region und der C-
Region wie in Fig. 1 dargestellt lokalisiert ist.
8. Verfahren nach Anspruch 7, femer dadurch gekennzeichnet, dass die spezifisch mit
der 22 Bp-Region nur eines HPV-Typs hybridisierende Sonde aus der folgenden Liste
ausgewählt ist:
HPV6 Pr1, HPV6 Pr2, HPV6 Pr3, HPV6 Pr4, HPV6 Pr5, HPV11 Pr1, HPV11 Pr2, HPV11 Pr3,
HPV11 Pr4, HPV11 Pr5, HPV16 Pr1, HPV16 Pr2, HPV16 Pr3, HPV16 Pr4, HPV16 Pr5,
HPV18 Pr1, HPV18 Pr2, HPV18 Pr3, HPV18 Pr4; HPV18 Pr5, HPV31 Pr1, HPV31 Pr2,
HPV31 Pr3, HPV31 Pr4, HPV31 Pr5, HPV31 Pr21, HPV31 Pr22, HPV31 Pr23, HPV31 Pr24,
HPV31 Pr25, HPV31 Pr26, HPV31 Pr31, HPV31 Pr32, HPV33 Pr1, HPV33 Pr2, HPV33 Pr3,
HPV33 Pr4, HPV33 Pr5, HPV33 Pr21, HPV33 Pr22, HPV33 Pr23, HPV33 Pr24, HPV33 Pr25,
HPV33 Pr26, HPV40 Pr1, HPV45 Pr1 (= SGPP68), HPV45 Pr2, HPV45 Pr3, HPV45 Pr4,
HPV45 Pr5, HPV45 Pi-11, HPV45 Pr12, HPV45 Prl3, HPV52 Pr1, HPV52 Pr2, HPV52 Pr3,
HPV52 Pr4. HPV52 Pr5, HPV52 Pr6, HPV56 Pr1, HPV56 Pr2, HPV56 Pr3, HPV56 Pr11,
HPV56 Pr12, HPV58 Pr1, HPV58 Pr2, HPV58 Pr3, HPV58 Pr4 (SEQ ID NO 24 bis 91), und,
SGPP35, SGPP39, SGPP51 (= HPV51 Pr1), SGPP54. SGPP59, SGPP66, SGPP70 ( = HPV70
Pr1), SGPP13, SGPP34, SGPP42, SGPP43, SGPP44, SGPP53, SGPP55. SGPP69, SGPP61,
SGPP62, SGPP64, SGPP67, SGPP74 (= HPV74 Prl3), MM4 ( = HPVM4 Pr1 l), mm.7, MM8
(SEQ ID NO 92 bis 115), und,
HPV18b Pr1, HPV18b Pr2, HPV31 Vs40-1, HPV31 Vs40-2, HPV31 Vs40-3, HPV34 Pr1,
HPV35 Pr1, HPV35 Pr2, HPV35 Pr3, HPV39 Pr1, HPV42 Pr1, HPV42 Pr2, HPV43 Pr1,
HPV43 Pr2, HPV43 Pr3, HPV44 Pr1, HPV44 Pr2, HPV44 Pr3. HPV44 Pr4, HPV51 Pr2,
HPV53 Pr1, HPV54 Pr1, HPV54 Pr11, HPV54 Pr11 as, HPV54 Pr12, HPV55 Pr1, HPV55 Pr11,
HPV55 Pr12, HPV55 Pr13, HPV56 Vs74-1, HPV59 Pr1. HPV59 Pril, HPV59 Pr12, HPV59
Pr-13, HPV66 Pr1, HPV67 Pr1, HPV67 Pril, HPV67 Pr12, HPV67 Pr13, HPV67 Pr21, HPV67
Pr22, HPV67 Pr23, HPV68 Pr1, HPV68 Pr2, HPV68 Pr3, HPV68 Vs45-1, HPV68 Vs45-2,
HPV70 Pr1, HPV70 Pr12, HPV70 Pr13, HPV74 Pr1, HPV74 Pr11, HPV74 Pr12, HPV74 Pr2,
HPV74 Pr3, HPVM4 Pr1, HPVM4 Pr12, HPVM4 Pr21, HPVM4 Pr22 (SEQ ID NO 161 bis
219).
9. Verfahren nach Anspruch 5, femer dadurch gekennzeichnet, dass die Sonde, die in der
Lage ist, spezifisch mit der D-Region des Genoms von mehr als einem HPV-Typ zu
hybridisieren, insbesondere mit der E-Region hybridisiert, wobei die E-Region eine
Subregion der D-Region wie in Fig. 1 dargestellt ist.
10. Verfahren nach Anspruch 9, femer dadurch gekennzeichnet, dass die mit der E-Region
von mehr als einem HPV-Typ spezifisch hybridisierende Sonde aus der folgenden Liste
ausgewählt ist:
HPVuni1, HPVuni2, HPVuni3, HPVuni4, HPVuni5, HPVuni6, HPVuni7, HPVuni2L2,
HPVuni2L3, HPVuni2L4, HPVuni2L5, HPVuni2L6, HPVuni2L7, HPVuni4L1, HPVuni4L2,
HPVuni4L3, HPVuni4L4, HPVuni4L5, HPVuni4L6 (SEQ ID NO 116 bis 134), und,
HPVuni1A, HPVuni1B, HPVuni1C, HPVuni2A, HPVuni3A (SEQ ID NO 220 bis 224), und,
HPV G1, HPV GIA1, HPV GIA2, HPV GIA3, HPV GIA4, HPV G2, HPV G3, HPV G4. HPV
G5, HPV G6, HPV R1, HPV R10, HPV R11, HPV R2, HPV R3, HPV R4, HPV R5, HPV R6,
HPV R7, HPV R8, HPV R9 (SEQ ID NO 225 bis 245).
11. Ein Primer wie in einem der Ansprüche 1 bis 3 definiert, zur Verwendung zum
Nachweis und/oder Identifizierung von HPV in einer biologischen Probe.
12. Eine Primerkombination bestehend aus einem 5'-Primer und einem 3'-Primer, beide
wie in einem der Ansprüche 1 bis 3 definiert, zur Verwendung zum Nachweis und/oder
Identifizierung von HPV in einer biologischen Probe.
13. Eine Sonde wie in einem der Ansprüche 1 und 4 bis 10 definiert, zur Verwendung zum
Nachweis und/oder Identifizierung von HPV in einer biologischen Probe.
14. Ein Diagnostik-Kit zum Nachweis und/oder Identifizierung von möglicherweise in
einer biologischen Probe vorliegendem HPV, umfassend die folgenden Bestandteile:
(i) mindestens eine Primerkombination nach Anspruch 12,
(ii) mindestens eine geeignete Sonde, wie sie in einem der Ansprüche 1 und 4 bis 10 definiert
ist.
15. Eine isolierte HPV Polynukleinsäure gemäß SEQ ID NO 135 bis 153 oder irgendein
Fragment davon, die oder das als Primer oder als Sonde in einem Verfahren zum Nachweis
und/oder Identifizierung von HPV in einer Probe verwendet werden kann.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97870136 | 1997-09-16 | ||
| PCT/EP1998/005829 WO1999014377A2 (en) | 1997-09-16 | 1998-09-14 | Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69806024D1 DE69806024D1 (de) | 2002-07-18 |
| DE69806024T2 true DE69806024T2 (de) | 2003-02-13 |
Family
ID=8231037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69806024T Expired - Lifetime DE69806024T2 (de) | 1997-09-16 | 1998-09-14 | Erkennung und identifizierung von menschlichem papillomavirus durch pcr und typ-spezifischer reverser hybridisierung |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6482588B1 (de) |
| EP (2) | EP1012348B1 (de) |
| AT (1) | ATE219153T1 (de) |
| AU (1) | AU9743398A (de) |
| CA (1) | CA2302146C (de) |
| DE (1) | DE69806024T2 (de) |
| DK (1) | DK1012348T3 (de) |
| ES (1) | ES2180207T3 (de) |
| HK (1) | HK1031238A1 (de) |
| PT (1) | PT1012348E (de) |
| WO (1) | WO1999014377A2 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100382703B1 (ko) | 2000-03-15 | 2003-05-09 | 주식회사 바이오메드랩 | 인유두종바이러스의 유전형 진단키트 및 상기 진단키트의제조방법 |
| US20020155427A1 (en) * | 2000-04-03 | 2002-10-24 | Cohenford Menashi A. | Detection and typing of human papillomavirus using PNA probes |
| US7439016B1 (en) * | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| GB0018050D0 (en) * | 2000-07-21 | 2000-09-13 | Norchip As | Detection of human papillomavirus mRNA |
| JP2004538010A (ja) * | 2001-08-08 | 2004-12-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アッセイ |
| KR100452163B1 (ko) * | 2001-09-14 | 2004-10-12 | 주식회사 바이오메드랩 | 인유두종 바이러스의 감염을 진단하기 위한 유전형 분석키트 |
| EP1302550A1 (de) * | 2001-10-10 | 2003-04-16 | King Car Food Industrial Co., Ltd. | Verfahren und Detektor für die Identifizierung von HPV Viren |
| HUP0200981A3 (en) * | 2002-03-14 | 2004-06-28 | Genoid Kft | Pcr reactions with hybridizing probes using primers with broad genotype-specificity for detection of human papilloma-viruses and typing amplificates by using specifically hybridizing oligonucleotides |
| EP1359192A1 (de) | 2002-04-30 | 2003-11-05 | Solvay Polyolefins Europe-Belgium (Société Anonyme) | Rohre aus Polyethylen |
| US7704965B2 (en) | 2002-06-26 | 2010-04-27 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
| US7452712B2 (en) | 2002-07-30 | 2008-11-18 | Applied Biosystems Inc. | Sample block apparatus and method of maintaining a microcard on a sample block |
| EP1403384A1 (de) * | 2002-09-26 | 2004-03-31 | Stichting Researchfonds Pathologie | Verfahren zum Nachweis und zur Karakterisierung von kutanem HPV und Primer und Sonden dafür |
| EP2031070B1 (de) | 2002-12-04 | 2013-07-17 | Life Technologies Corporation | Multiplexverstärkung von Polynucleotiden |
| US20060024690A1 (en) * | 2003-09-19 | 2006-02-02 | Kao H P | Normalization of data using controls |
| US20050112634A1 (en) * | 2003-09-19 | 2005-05-26 | Woudenberg Timothy M. | High density sequence detection methods and apparatus |
| US7527948B2 (en) | 2003-09-25 | 2009-05-05 | Third Wave Technologies, Inc. | Detection of HPV |
| WO2005033333A2 (en) | 2003-10-07 | 2005-04-14 | Dako Denmark A/S | Methods and compositions for the diagnosis of cancer |
| WO2005085475A1 (en) | 2004-03-01 | 2005-09-15 | Applera Corporation | Methods, compositions and kits for use in polynucleotide amplification |
| US7482142B1 (en) | 2004-05-07 | 2009-01-27 | Roche Molecular Systems, Inc. | High-risk human papillomavirus detection |
| US20050255485A1 (en) * | 2004-05-14 | 2005-11-17 | Livak Kenneth J | Detection of gene duplications |
| US20060003337A1 (en) * | 2004-06-30 | 2006-01-05 | John Brandis | Detection of small RNAS |
| US7670774B2 (en) * | 2004-10-04 | 2010-03-02 | Goodgene Inc. | Probe of human papillomavirus and DNA chip comprising the same |
| US7901883B2 (en) * | 2004-12-10 | 2011-03-08 | Genera Biosystems Limited | Human papilloma virus (HPV) detection using nucleic acid probes, microbeads and fluorescent-activated cell sorter (FACS) |
| GB0500996D0 (en) * | 2005-01-18 | 2005-02-23 | Delfts Diagnostic Labaratory B | Detection method and materials therefor |
| US8927208B2 (en) * | 2005-03-30 | 2015-01-06 | Labo Bio-Medical Investments B.V. | Identification of beta-papillomavirus DNA by type-specific reverse hybridization |
| US20070031826A1 (en) * | 2005-08-05 | 2007-02-08 | My Gene | Diagnostic kit for determining the genotype of a human papilloma virus and method of using thereof |
| GB0516145D0 (en) * | 2005-08-05 | 2005-09-14 | Genomica Sau | In vitro diagnostic kit for identification of human papillomavirus in clinical samples |
| KR20080084809A (ko) * | 2005-11-15 | 2008-09-19 | 게노이드 케이에프티. | 병원체를 검출하는 방법 |
| US8841069B2 (en) * | 2005-12-29 | 2014-09-23 | Korea Materials & Analysis Corporation | Dendron-mediated DNA virus detection |
| KR100702415B1 (ko) * | 2006-03-03 | 2007-04-09 | 안웅식 | 올리고 핵산 탐침 비드 어레이를 이용한 인유두종바이러스검출 키트 및 방법 |
| EP3167900B1 (de) | 2006-03-29 | 2018-11-21 | Merial Limited | Impfstoff gegen streptokokken |
| ZA200901744B (en) * | 2006-08-11 | 2010-10-27 | Chu Sainte Justine | Oligonucleotides for discriminating related nucleic acid sequences |
| US8080643B2 (en) * | 2006-09-05 | 2011-12-20 | Third Wave Technologies, Inc. | HPV primers |
| ATE518958T1 (de) | 2007-01-30 | 2011-08-15 | Transgene Sa | Zur impfung verwendetes papillomavirus-e2- polypeptid |
| GB0702557D0 (en) * | 2007-02-09 | 2007-03-21 | Health Prot Agency | Detection of human papillomavirus |
| ES2403729T3 (es) * | 2007-04-05 | 2013-05-21 | Genera Biosystems Limited | Composiciones y métodos de detección |
| EP1997914A1 (de) * | 2007-06-01 | 2008-12-03 | Università Degli Studi Di Milano - Bicocca | Identifizierung und Quantifizierung onkogener HPV-Nukleinsäuren mittels PCR-Assays in Echtzeit |
| ES2584228T3 (es) * | 2007-11-01 | 2016-09-26 | Self-Screen B.V. | Nuevo método de detección para los HPV cervicales |
| US9090948B2 (en) | 2008-09-30 | 2015-07-28 | Abbott Molecular Inc. | Primers and probes for detecting human papillomavirus and human beta globin sequences in test samples |
| GB0820822D0 (en) | 2008-11-13 | 2008-12-24 | Inst Catala D Oncologia | Novel product and processes |
| WO2010058357A1 (en) | 2008-11-19 | 2010-05-27 | Diagcor Bioscience Incorporation Ltd. | Nucleotide sequences, methods and kits for detecting hpv |
| NO330943B1 (no) * | 2009-04-30 | 2011-08-22 | Unilabs Telelabs As | En metode for detektering og/eller typebestemmelse og/eller kvantifisering av human papillomavirus (HPV) type, primere og prober derav samt diagnostisk sett og anvendelse derav. |
| CN102497880A (zh) | 2009-06-25 | 2012-06-13 | 葛兰素史密丝克莱恩生物有限公司 | 新的人***状瘤病毒(hpv)蛋白构建体及其在预防hpv疾病中的用途 |
| ES2357821B8 (es) * | 2009-07-07 | 2012-03-05 | Universidad Politécnica De Cartagena | Método para la detección y determinación de carga viral del virus del papiloma humano. |
| JP6153866B2 (ja) | 2010-05-25 | 2017-06-28 | キアゲン ガイサーズバーグ アイエヌシー． | 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ |
| EP2703496A1 (de) | 2012-08-31 | 2014-03-05 | Innogenetics N.V. | Kombination von PCR-Primern und Verfahren zur Erkennung und Identifizierung des humanen Papillomvirus (HPV) |
| WO2014134607A1 (en) * | 2013-03-01 | 2014-09-04 | The Johns Hopkins University | Dual sequence-capture method for quantifying trans renal hpv dna in urine |
| GB201511470D0 (en) * | 2015-06-30 | 2015-08-12 | Cellcall Kft | HPV detection method |
| CN106939359A (zh) * | 2017-05-17 | 2017-07-11 | 上海市第十人民医院 | 一种lamp法检测hpv常见亚型的引物组及检测体系 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182377A (en) * | 1988-09-09 | 1993-01-26 | Hoffmann-La Roche Inc. | Probes for detection of human papillomavirus |
| US5639871A (en) * | 1988-09-09 | 1997-06-17 | Roche Molecular Systems, Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| US5447839A (en) * | 1988-09-09 | 1995-09-05 | Hoffmann-La Roche Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| NL9000134A (nl) * | 1990-01-19 | 1991-08-16 | Stichting Res Fonds Pathologie | Primers en werkwijze voor het detecteren van humaan papilloma virus genotypen m.b.v. pcr. |
-
1998
- 1998-09-14 WO PCT/EP1998/005829 patent/WO1999014377A2/en active IP Right Grant
- 1998-09-14 DK DK98951392T patent/DK1012348T3/da active
- 1998-09-14 AT AT98951392T patent/ATE219153T1/de active
- 1998-09-14 EP EP98951392A patent/EP1012348B1/de not_active Expired - Lifetime
- 1998-09-14 EP EP01204423A patent/EP1201771A3/de not_active Withdrawn
- 1998-09-14 PT PT98951392T patent/PT1012348E/pt unknown
- 1998-09-14 ES ES98951392T patent/ES2180207T3/es not_active Expired - Lifetime
- 1998-09-14 DE DE69806024T patent/DE69806024T2/de not_active Expired - Lifetime
- 1998-09-14 AU AU97433/98A patent/AU9743398A/en not_active Abandoned
- 1998-09-14 CA CA2302146A patent/CA2302146C/en not_active Expired - Lifetime
-
2000
- 2000-03-16 US US09/527,030 patent/US6482588B1/en not_active Expired - Lifetime
- 2000-12-21 HK HK00108367A patent/HK1031238A1/xx not_active IP Right Cessation
-
2002
- 2002-09-11 US US10/241,780 patent/US20030165821A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1201771A3 (de) | 2002-10-23 |
| ES2180207T3 (es) | 2003-02-01 |
| WO1999014377A2 (en) | 1999-03-25 |
| DE69806024D1 (de) | 2002-07-18 |
| HK1031238A1 (en) | 2001-06-08 |
| AU9743398A (en) | 1999-04-05 |
| EP1012348A2 (de) | 2000-06-28 |
| EP1012348B1 (de) | 2002-06-12 |
| DK1012348T3 (da) | 2002-10-14 |
| EP1201771A2 (de) | 2002-05-02 |
| WO1999014377A3 (en) | 1999-06-17 |
| CA2302146C (en) | 2010-07-13 |
| PT1012348E (pt) | 2002-11-29 |
| ATE219153T1 (de) | 2002-06-15 |
| US6482588B1 (en) | 2002-11-19 |
| CA2302146A1 (en) | 1999-03-25 |
| US20030165821A1 (en) | 2003-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69806024T2 (de) | Erkennung und identifizierung von menschlichem papillomavirus durch pcr und typ-spezifischer reverser hybridisierung | |
| DE69527776T2 (de) | Nachweis humaner papillomviren mit nukleinsäüre amplifikation die generelle primer verwendet | |
| Molijn et al. | Molecular diagnosis of human papillomavirus (HPV) infections | |
| DE3853678T2 (de) | Verfahren zum nachweis des karzinogenen menschlichen papillomavirus. | |
| EP1838881B1 (de) | Verfahren zum nachweis von hpv sowie sonden, primer und kits | |
| DE68918237T2 (de) | DNS-Sequenzen des menschlichen Papillomavirus Typ 52 und Verfahren zu ihrer Verwendung. | |
| NZ533703A (en) | Method for detecting human papillomavirus mRNA | |
| DE60308017T2 (de) | Amplifizierungs-hybridisierungsverfahren zum nachweis und zur typisierung des mes menschlichen papillomavirus | |
| Arends et al. | HPV in full thickness cervical biopsies: high prevalence in CIN 2 and CIN 3 detected by a sensitive PCR method | |
| DE69121821T2 (de) | Nukleotid-Sequenzen nützlich als typenspezifische Sonden, PCR Primers und LCR Sonden zur Amplifikation und zum Nachweis von humanem Papillomavirus, sowie dazu verwendete Kits und Verfahren | |
| Williamson et al. | Detection of genital human papillomaviruses by polymerase chain reaction amplification with degenerate nested primers | |
| WO1989009940A1 (en) | Human papilloma virus typing method and nucleic acid probes used therein | |
| EP2062984B1 (de) | Primer und Sonden zum Nachweis genitaler HPV-Genotypen | |
| EP1272675B1 (de) | Nachweis von humanen papillomviren | |
| KR100437626B1 (ko) | 인간 유두종바이러스 유전자형 검사 방법과 이를 위한검사 키트 | |
| EP2336369A1 (de) | Sonden zur Genotypisierung von risikoarmen HPV | |
| KR100979271B1 (ko) | 인간 유두종바이러스 유전자형 검사용 유전자칩, 키트 및그를 이용한 검사 방법 | |
| KR100988755B1 (ko) | 네스티드 рсｒ을 이용한 ｈｐｖ ｌ1 유전자 검출방법 | |
| JP2008526242A (ja) | Ｈｐｖ１６型系統群の同定 | |
| Shikova et al. | PCR WITH THE E6/E7 PRIMER SETS IMPROVES DETECTION OF HUMAN PAPILLOMAVIRUS TYPE 16 DNA IN CERVICAL SAMPLES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |